Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Declan G Murphy

Showing results (371-380 of 415) with videos related to

Pageof 42
Sort By:
European Urology Oncology|June 13, 2022
EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [<sup>177</sup>Lu]Lu-PSMA Radioligand TherapyStefano Fanti, Alberto Briganti, Louise Emmett, et al.
Lancet (London, England)|March 27, 2020
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre studyMichael S Hofman, Nathan Lawrentschuk, Roslyn J Francis, et al.
The Journal of Urology|April 28, 2025
Pelvic Lymph Node Dissection in Prostate Cancer: Is It Really Necessary? A Multicentric Longitudinal Study Assessing Oncological Outcomes in Patients With Prostate Cancer Patients Undergoing Pelvic Lymph Node Dissection vs Radical Prostatectomy OnlyMarc A Furrer, Niranjan J Sathianathen, Clancy J Mulholland, et al.
European Urology Oncology|November 29, 2024
Baseline Nodal Status on <sup>68</sup>Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA TrialMichael S Hofman, Veeru Kasivisvanathan, Emma Link, et al.
The Lancet. Oncology|September 18, 2024
Sequential [<sup>177</sup>Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 studyArun A Azad, Mathias Bressel, Hsiang Tan, et al.
Prostate Cancer and Prostatic Diseases|January 15, 2020
"TREXIT 2020": why the time to abandon transrectal prostate biopsy starts nowJeremy Grummet, Michael A Gorin, Rick Popert, et al.
European Urology Oncology|May 7, 2025
Early Results from the CONFIRM Trial: Utility of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Active Surveillance for Prostate CancerJianliang Liu, Laurence Harewood, Dominic Bagguley, et al.
European Urology|October 27, 2023
Administering [<sup>177</sup>Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 StudyRenu S Eapen, James P Buteau, Price Jackson, et al.
Prostate International|August 7, 2019
Report of the third Asian Prostate Cancer study meetingBannakij Lojanapiwat, Ji Youl Lee, Zhu Gang, et al.
Nature Communications|November 18, 2020
Author Correction: Transcriptomic and cellular decoding of regional brain vulnerability to neurogenetic disordersJakob Seidlitz, Ajay Nadig, Siyuan Liu, et al.
Pageof 42

Showing results (371-380 of 415) with videos related to

Sort By:
Pageof 42
European Urology Oncology|June 13, 2022
EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [<sup>177</sup>Lu]Lu-PSMA Radioligand TherapyStefano Fanti, Alberto Briganti, Louise Emmett, et al.
Lancet (London, England)|March 27, 2020
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre studyMichael S Hofman, Nathan Lawrentschuk, Roslyn J Francis, et al.
The Journal of Urology|April 28, 2025
Pelvic Lymph Node Dissection in Prostate Cancer: Is It Really Necessary? A Multicentric Longitudinal Study Assessing Oncological Outcomes in Patients With Prostate Cancer Patients Undergoing Pelvic Lymph Node Dissection vs Radical Prostatectomy OnlyMarc A Furrer, Niranjan J Sathianathen, Clancy J Mulholland, et al.
European Urology Oncology|November 29, 2024
Baseline Nodal Status on <sup>68</sup>Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA TrialMichael S Hofman, Veeru Kasivisvanathan, Emma Link, et al.
The Lancet. Oncology|September 18, 2024
Sequential [<sup>177</sup>Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 studyArun A Azad, Mathias Bressel, Hsiang Tan, et al.
Prostate Cancer and Prostatic Diseases|January 15, 2020
"TREXIT 2020": why the time to abandon transrectal prostate biopsy starts nowJeremy Grummet, Michael A Gorin, Rick Popert, et al.
European Urology Oncology|May 7, 2025
Early Results from the CONFIRM Trial: Utility of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Active Surveillance for Prostate CancerJianliang Liu, Laurence Harewood, Dominic Bagguley, et al.
European Urology|October 27, 2023
Administering [<sup>177</sup>Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 StudyRenu S Eapen, James P Buteau, Price Jackson, et al.
Prostate International|August 7, 2019
Report of the third Asian Prostate Cancer study meetingBannakij Lojanapiwat, Ji Youl Lee, Zhu Gang, et al.
Nature Communications|November 18, 2020
Author Correction: Transcriptomic and cellular decoding of regional brain vulnerability to neurogenetic disordersJakob Seidlitz, Ajay Nadig, Siyuan Liu, et al.
Pageof 42